April 24, 2025

FDA Warns of Topical Finasteride Risks

The FDA has issued a safety alert on compounded topical finasteride products, citing adverse events and emphasizing the lack of regulatory approval or safety evaluation.

Conexiant

April 24, 2025

Medical Oddities: Back Pain’s Cellular Villains Found?

Back pain’s got villains, green tea’s got perks, and empathy might outlast your logic this week.

Conexiant

April 23, 2025

Long-Term EEG Monitoring Now Authorized in the United States

The FDA has authorized Minder, the first implantable continuous electroencephalogram monitor, offering long-term brain activity tracking for improved epilepsy management, available in the U.S.

Conexiant

April 23, 2025

FDA Targets Petroleum-Based Dyes in Food Supply

The FDA and HHS announced plans to eliminate petroleum-based synthetic food dyes, citing potential health risks and aligning with global safety standards.

Conexiant

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 22, 2025

Eating Disorders Prevalent Among Male Populations

"Over 1 in 5 participants met criteria for any probable eating disorder diagnosis," reports new research that examined eating disorder prevalence among 1,553 boys and men in Canada and the U.S.

Conexiant

April 22, 2025

National Survey Reveals Sex Shift in Alcohol Use

Past-month binge drinking among young adult females in 2021-2023 was higher than males.

Conexiant

April 21, 2025

New Findings Show No Difference in IGE Treatment Strategies

A study found no statistically significant differences in treatment failure rates between substitution monotherapy and add-on therapy for women with idiopathic generalized epilepsy, indicating both options are viable.

Conexiant

April 21, 2025

New Prescription App Reduces Migraine Days

The FDA has authorized CT-132, the first prescription digital therapeutic for episodic migraine prevention, based on clinical trial data showing reduced monthly migraine days.

Conexiant